Discovery and preclinical characterization of BAY 1905254 a novel immune checkpoint inhibitor for cancer immunotherapy targeting the immunoglobulin-like domain containing receptor 2 (ILDR2)

被引：1

作者：

Huetter, Julia ^{[1
]}

Gritzan, Uwe ^{[2
]}

Gutcher, Ilona ^{[1
]}

Golfier, Sven ^{[1
]}

Doecke, Wolf-Dietrich ^{[1
]}

Luetke-Eversloh, Merlin Verena ^{[1
]}

Roider, Helge ^{[1
]}

Hunter, John ^{[3
]}

Pow, Andrew ^{[4
]}

Liang, Spencer ^{[3
]}

Levine, Zurit ^{[5
]}

Levy, Ofer ^{[5
]}

Vaaknin, Ilan ^{[5
]}

Kreft, Bertolt ^{[1
]}

Roese, Lars ^{[1
]}

机构：

[1] Bayer AG, Berlin, Germany

[2] Bayer AG, Cologne, Germany

[3] Compugen, San Francisco, CA USA

[4] New Paradigm Biosci, Woburn, MA USA

[5] Compugen, Holon, Israel

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-2778

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2778

引用

页数：2

共 17 条

[1] Characterization of BAY1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
Huetter, Julia
Gritzan, Uwe
Gutcher, Ilona
Doecke, Wolf-Dietrich
Luetke-Eversloh, Merlin V.
Golfier, Sven
Roider, Helge G.
Frisk, Anna-Lena
Hunter, John
Pow, Andrew
Drake, Andrew
Levine, Zurit
Levy, Ofer
Azulay, Meir
Barbiro, Inbal
Cojocaru, Gady
Vaknin, Ilan
Kreft, Bertolt
Roese, Lars
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (07) : 895 - 911
[2] Characterization of a novel immunoglobulin-like domain containing receptor
Hauge, H
Patzke, S
Delabie, J
Aasheim, HC
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 323 (03) : 970 - 978
[3] A NOVEL MUTATION AFFECTING THE 2ND IMMUNOGLOBULIN-LIKE DOMAIN OF THE HUMAN KIT RECEPTOR
FLEISCHMAN, RA
BLOOD, 1993, 82 (10) : A231 - A231
[4] Immunoglobulin-like domain-containing receptor 2 deficiency aggravates ischemia-reperfusioninduced renal fibrosis
徐梦园
ChinaMedicalAbstracts(InternalMedicine), 2023, 40 (02) : 112 - 113
[5] KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR 2DL2 (KIR2DL2) IMMUNE CHECKPOINT AS A MODULATOR OF T-CELL EFFECTOR FUNCTION
Fontela, Miguel Gomez
Snedal, Sebastian
Abate-Daga, Daniel
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A239 - A239
[6] Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) immune checkpoint modulates CAR-T cell effector function
Fontela, Miguel Gomez
Snedal, Sebastian
Planes, Elena Martinez
Abate-Daga, Daniel
CANCER RESEARCH, 2023, 83 (07)
[7] Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes
Kang, Minsung
Kim, Chijung
Leem, Jiyeon
Kim, Ye-hyun
Kwon, Young-ju
Yoon, Yi Na
Chae, Chong Hak
Ahn, Jiyeon
Jung, Kwan-Young
Oh, Jeong Su
Kim, Jae-Sung
PHARMACEUTICALS, 2021, 14 (07)
[8] Discovery and characterization of a novel triple A1/A2a/A2b adenosine receptor antagonist for cancer immunotherapy.
Jang, Sunyoung
Jun, Seunah
Lee, Hosun
Lee, Yongtaek
Byun, Joo-Yun
Park, Junghwa
Kim, Yu-Yon
Ahn, Young Gil
Suh, Kwee Hyun
CANCER RESEARCH, 2021, 81 (13)
[9] Discovery and characterization of INCB106385: a novel A2A/A2B adenosine receptor antagonist, as a cancer immunotherapy.
Wang, Hui
Alexandra, Alexandra
Hansbury, Michael
Mason, Jennifer
Harris, Jennifer
Stevens, Christina
Maddage, Christopher
Ren, Xiaodi
Gao, Mingming
Kurzeja-Lipinski, Kerri
Yang, Gengjie
Conlen, Patricia
Stump, Kristine
Feldman, Patricia
Thekkat, Pramod
Lin, Luping
Covington, Maryanne
Yeleswaram, Swamy
Qi, Chao
Wang, Xiaozhao
Yao, Wenqing
Kim, Sunkyu
Wee, Susan
Chen, Yingnan
Koblish, Holly
CANCER RESEARCH, 2021, 81 (13)
[10] TT-816, A NOVEL SMALL MOLECULE IMMUNE CHECKPOINT INHIBITOR TARGETING CANNABINOID CB2 RECEPTOR, STIMULATES INNATE AND ADAPTIVE IMMUNITY FOR CANCER THERAPY
Fan, Peidong
Elzein, Elfatih
Yao, Lina
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1001 - A1001

← 1 2 →